299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details


臨床試験数 : 1,696 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-004263-36-DE
(EUCTR)
13/11/201706/09/2017Study to assess the effects of inhaled RPL554 in adults with cystic fibrosis.A Phase IIa, randomised, double blind, placebo controlled, three way crossover study to assess the pharmacokinetics of RPL554 administered to adult patients with Cystic Fibrosis. - Study to assess the effects of inhaled RPL554 in patients with cystic fibrosis. Cystic Fibrosis (CF)
MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Product Name: RPL554
Product Code: RPL554
INN or Proposed INN: RPL554
Other descriptive name: RPL554
Verona Pharma plcNULLNot RecruitingFemale: yes
Male: yes
10Phase 2Germany;United Kingdom
2NCT02919995
(ClinicalTrials.gov)
February 8, 201721/9/2016A Study of RPL554 in Patients With Cystic FibrosisA Phase IIa, Randomised, Double Blind, Placebo Controlled, Three Way Crossover Study to Assess the Pharmacokinetics of RPL554 Administered to Adult Patients With Cystic Fibrosis.Cystic FibrosisDrug: RPL554;Drug: PlaceboVerona Pharma plcCystic Fibrosis TrustCompleted18 YearsN/AAll10Phase 2United Kingdom
3EUCTR2015-004263-36-GB
(EUCTR)
07/12/201630/08/2016Study to assess the effects of inhaled RPL554 in adults with cystic fibrosis.A Phase IIa, randomised, double blind, placebo controlled, three way crossover study to assess the pharmacokinetics of RPL554 administered to adult patients with Cystic Fibrosis. - To assess the effects of inhaled RPL554 in adults with cystic fibrosis Cystic Fibrosis (CF)
MedDRA version: 20.0;Level: PT;Classification code 10011762;Term: Cystic fibrosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Product Name: RPL554
Product Code: RPL554
INN or Proposed INN: RPL554
Other descriptive name: RPL554
Verona Pharma plcNULLNot Recruiting Female: yes
Male: yes
10 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noGermany;United Kingdom